Literature DB >> 36050971

Current perspective of immunomodulators for lung transplant.

Dhruva Sharma1, Ganapathy Subramaniam Krishnan2, Neha Sharma3, Anitha Chandrashekhar2.   

Abstract

Lung transplantation is an effective treatment option for selected patients suffering from end-stage lung disease. More intensive immunosuppression is enforced after lung transplants owing to a greater risk of rejection than after any other solid organ transplants. The commencing of lung transplantation in the modern era was in 1983 when the Toronto Lung Transplant Group executed the first successful lung transplant. A total of 43,785 lung transplants and 1365 heart-lung transplants have been performed from 1 Jan 1988 until 31 Jan 2021. The aim of this review article is to discuss the existing immunosuppressive strategies and emerging agents to prevent acute and chronic rejection in lung transplantation. © Indian Association of Cardiovascular-Thoracic Surgeons 2022.

Entities:  

Keywords:  Immunosuppressants; Induction immunosuppression; Lung transplantation; Maintenance immunosuppression

Year:  2022        PMID: 36050971      PMCID: PMC9424406          DOI: 10.1007/s12055-022-01388-1

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  54 in total

1.  Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.

Authors:  Jian Wang; Adriana Zeevi; Kenneth McCurry; Erin Schuetz; Hongxia Zheng; Aldo Iacono; Kevin McDade; Diana Zaldonis; Steven Webber; Richard M Watanabe; Gilbert J Burckart
Journal:  Transpl Immunol       Date:  2005-09-08       Impact factor: 1.708

Review 2.  Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.

Authors:  Nowell M Fine; Sudhir S Kushwaha
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

Review 3.  Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.

Authors:  Anthony C Allison; Elsie M Eugui
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

Review 4.  Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation.

Authors:  Amanda L Hulbert; Elizabeth N Pavlisko; Scott M Palmer
Journal:  Curr Opin Organ Transplant       Date:  2018-06       Impact factor: 2.640

Review 5.  Living-related lung transplantation.

Authors:  Hiroshi Date
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 6.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

7.  Survival in sensitized lung transplant recipients with perioperative desensitization.

Authors:  K J Tinckam; S Keshavjee; C Chaparro; D Barth; S Azad; M Binnie; C W Chow; M de Perrot; A F Pierre; T K Waddell; K Yasufuku; M Cypel; L G Singer
Journal:  Am J Transplant       Date:  2015-02       Impact factor: 8.086

8.  Antibody desensitization therapy in highly sensitized lung transplant candidates.

Authors:  L D Snyder; A L Gray; J M Reynolds; G M Arepally; A Bedoya; M G Hartwig; R D Davis; K E Lopes; W E Wegner; D F Chen; S M Palmer
Journal:  Am J Transplant       Date:  2014-02-19       Impact factor: 8.086

9.  Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.

Authors:  Andrew M Courtwright; Malek Kamoun; Joshua M Diamond; Jane Kearns; Vivek N Ahya; Jason D Christie; Emily Clausen; Denis Hadjiliadis; Namrata Patel; Juan C Salgado; Marisa Cevasco; Edward E Cantu; Maria M Crespo; Christian A Bermudez
Journal:  Clin Transplant       Date:  2021-09-12       Impact factor: 2.863

Review 10.  Individualizing immunosuppression in lung transplantation.

Authors:  Jennifer K McDermott; Reda E Girgis
Journal:  Glob Cardiol Sci Pract       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.